Literature DB >> 10383559

Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

A Rostami-Hodjegan1, K Wolff, A W Hay, D Raistrick, R Calvert, G T Tucker.   

Abstract

AIMS: Although methadone is widely used to treat opiate dependence, guidelines for its dosage are poorly defined. There is increasing evidence to suggest that a strategy based on plasma drug monitoring may be useful to detect non-compliance. Therefore, we have developed a population-based pharmacokinetic (POP-PK) model that characterises adaptive changes in methadone kinetics.
METHODS: Sparse plasma rac-methadone concentrations measured in 35 opiate-users were assessed using the P-Pharm software. The final structural model comprised a biexponential function with first-order input and allowance for time-dependent change in both clearance (CL) and initial volume of distribution (V ). Values of these parameters were allowed to increase or decrease exponentially to an asymptotic value.
RESULTS: Increase in individual values of CL and increase or decrease in individual values of V with time was observed in applying the model to the experimental data.
CONCLUSIONS: A time-dependent increase in the clearance of methadone is consistent with auto-induction of CYP3A4, the enzyme responsible for much of the metabolism of the drug. The changes in V with time might reflect both up- and down-regulation of alpha1-acid glycoprotein, the major plasma binding site for methadone. By accounting for adaptive kinetic changes, the POP-PK model provides an improved basis for forecasting plasma methadone concentrations to predict and adjust dosage of the drug and to monitor compliance in opiate-users on maintenance treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383559      PMCID: PMC2014882          DOI: 10.1046/j.1365-2125.1999.00974.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  41 in total

1.  The use of plasma levels to optimize methadone maintenance treatment.

Authors:  N Loimer; R Schmid
Journal:  Drug Alcohol Depend       Date:  1992-08       Impact factor: 4.492

2.  Characterization of the stereoselective metabolism of methadone and its primary metabolite via cyclodextrin capillary electrophoretic determination of their urinary enantiomers.

Authors:  M Lanz; W Thormann
Journal:  Electrophoresis       Date:  1996-12       Impact factor: 3.535

3.  Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.

Authors:  Z Hussein; J Posner
Journal:  Br J Clin Pharmacol       Date:  1997-05       Impact factor: 4.335

4.  Kinetic models of induction: I. Persistence of the inducing substance.

Authors:  F P Abramson
Journal:  J Pharm Sci       Date:  1986-03       Impact factor: 3.534

5.  Plasma methadone monitoring with methadone maintenance treatment.

Authors:  K Wolff; A W Hay
Journal:  Drug Alcohol Depend       Date:  1994-08       Impact factor: 4.492

6.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.

Authors:  C B Eap; G Bertschy; K Powell; P Baumann
Journal:  J Clin Psychopharmacol       Date:  1997-04       Impact factor: 3.153

8.  Disposition of methadone in methadone maintenance.

Authors:  E Anggård; L M Gunne; J Homstrand; R E McMahon; C G Sandberg; H R Sullivan
Journal:  Clin Pharmacol Ther       Date:  1975-03       Impact factor: 6.875

9.  Methadone binding to orosomucoid (alpha 1-acid glycoprotein): determinant of free fraction in plasma.

Authors:  M K Romach; K M Piafsky; J G Abel; V Khouw; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1981-02       Impact factor: 6.875

10.  Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone.

Authors:  U Schall; E Pries; T Katta; A Klöppel; M Gastpar
Journal:  Addict Biol       Date:  1996       Impact factor: 4.280

View more
  26 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Toxicology and pathology of deaths related to methadone: retrospective review.

Authors:  S B Karch; B G Stephens
Journal:  West J Med       Date:  2000-01

3.  Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz.

Authors:  Rosario Calvo; John C Lukas; Monica Rodriguez; M Angeles Carlos; Elena Suarez
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

4.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

Review 5.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 6.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.

Authors:  Peter L Bonate; Simon Floret; Craig Bentzen
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 8.  Neonatal abstinence syndrome: treatment and pediatric outcomes.

Authors:  Beth A Logan; Mark S Brown; Marie J Hayes
Journal:  Clin Obstet Gynecol       Date:  2013-03       Impact factor: 2.190

9.  Sex specificity in methadone analgesia in the rat: a population pharmacokinetic and pharmacodynamic approach.

Authors:  Monica Rodriguez; M Angeles Carlos; Ignacio Ortega; Elena Suarez; Rosario Calvo; John C Lukas
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.